<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536237</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-011</org_study_id>
    <secondary_id>MK0524A-011</secondary_id>
    <secondary_id>2007_618</secondary_id>
    <nct_id>NCT00536237</nct_id>
  </id_info>
  <brief_title>MK0524A Phase IIb Study (0524A-011)(COMPLETED)</brief_title>
  <official_title>Part A: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of MK0524 Compared to Placebo Part B: A Dose-Ranging Study to Evaluate the Tolerability of MK0524 and Its Effects on Niacin-Induced Flushing in Lipid Clinic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      Part A: This study will determine that MK0524 is well tolerated and does not effect lipids
      and blood glucose when given alone.

      Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids
      and blood glucose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of MK0524A on lipids and blood glucose</measure>
    <time_frame>17 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To establish the dose for limiting flushing symptoms induced by NIASPAN (R)</measure>
    <time_frame>17 Weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">154</enrollment>
  <condition>Flushing</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: niacin / Duration of Treatment: 17 Weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, 18 to 70 years of age for whom treatment with Niacin would be
             appropriate but who are not taking &gt; 50mg at screening

          -  Must be willing to complete electronic diary

        Exclusion Criteria:

          -  Subject is having menopausal hot flashes and/or receiving hormone replacement therapy
             (HRT)

          -  You have a history of cancer, gout, peptic ulcers, diabetes, liver, heart disease or
             high blood pressure or you are HIV positive

          -  You consume more than 14 alcoholic drinks per week or more than 2 drinks per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <reference>
    <citation>Paolini JF, Mitchel YB, Reyes R, Kher U, Lai E, Watson DJ, Norquist JM, Meehan AG, Bays HE, Davidson M, Ballantyne CM. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008 Mar 1;101(5):625-30. doi: 10.1016/j.amjcard.2007.10.023. Epub 2007 Dec 21.</citation>
    <PMID>18308010</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2007</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

